Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC

NCT04028778 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

310

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer, Nonsmall Cell

Interventions

DRUG: Gefitinib
DRUG: Anlotinib Hydrochloride
OTHER: Placebo

Sponsor

Sun Yat-sen University